Introduction
Monoclonal gammopathies result from the activation of clonal B cells/plasma cells
that secrete a particular type of immunoglobulin, called monoclonal protein or M protein
and whose levels may remain stable or progress over time.
1
Monoclonal gammopathy of undetermined significance is the most common form and is
considered a non-malignant or pre-malignant condition. It is more prevalent in advanced
ages affecting about 3% of the over 50-year-old population. It is defined as the presence
of M protein in serum of less than 3.0 g/dL and/or in urine of less than 1 g in a
24-h urine sample, plasma cell infiltration of the bone marrow corresponding to less
than 10% of the total nucleated cells and the absence of lesions in target organs
and tissues.
2
The term monoclonal gammopathy of renal significance, proposed in 2012 by the International
Kidney and Monoclonal Gammopathy Research Group, is relatively recent. It applies
to cases that do not meet the diagnostic criteria for multiple myeloma and the renal
damage secondary to M protein (both by direct and indirect mechanisms) and do not
allow a diagnosis of monoclonal gammopathy of undetermined significance.
3
Case report
This is the case of a 77-year-old woman, hospitalized in the Nephrology Unit in February
2017 due to renal insufficiency lasting for one year, with progressive worsening.
She waited for about six months before being attended by the specialty. The patient
presented arterial hypertension and malleolar edema with, at the time of admission,
emergency renal replacement therapy being indicated due to hypervolemia. Besides the
renal condition, she presented bicytopenia (anemia and thrombocytopenia) and despite
negative serum protein electrophoresis and negative immunofixation of serum proteins,
immunofixation of urinary proteins showed a pattern suggestive of immunoglobulin G
(IgG)/Kappa restriction. The term ‘suggestive’ was used by the laboratory to describe
a monoclonal band of tenuous limits but able to maintain its meaning, proving the
presence of clonality in this case. The free light chain assay was not performed due
to the unavailability of this exam in the service where the patient was treated. However,
it was possible to define clonality through immunofixation of urinary proteins.
Considering the possibility of a disease in the spectrum of monoclonal gammopathies,
a myelogram with a representative sample and a bone marrow biopsy with morphological
and immunohistochemical evaluations were performed but showed no evidence of plasma
cell infiltration (which excluded multiple myeloma). A renal biopsy revealed a membranoproliferative
pattern at light microscopy (Figure 1A–D) and an investigation of β-fibrillose by
Congo red staining was negative. Subendothelial deposits of IgG (Figure 1E), Kappa,
Lambda, C3 and C1q were identified in glomeruli by immunofluorescence. Electron microscopy
showed mesangial and subendothelial fibrillary deposits (Figure 1F–H). A diagnosis
of monoclonal gammopathy of renal significance was reached after excluding other etiologies
for renal failure. In this case, there was no benefit in chemotherapeutic treatment
as it was already an end-stage renal disease and there was no perspective of renal
transplantation.
Figure 1
(A–D) Glomeruli with increased volume, lobulated aspect, endocapillary hypercellularity
with reduced capillary lumen and increased mesangial matrix. In addition, there are
double contours in some capillary loops. (A) Hematoxylin eosin; (B) Sirius Red; (C)
Periodic acid silver methenamine stain (PAMS); (D) Masson Trichrome – magnification:
20×. (E) Immunofluorescence for immunoglobulin G showing accentuated deposition in
capillary loops, subendothelial glomerulus. (F and G) Enlargement of subendothelial
space with randomly distributed fibrils and mesangial interposition (transmission
electron microscopy: F – 7000×; G – 12,000×) and (H) detail of the deposit of fibrillary
material (transmission electron microscopy: 30,000×).
Discussion
In the present case, a patient with nephrotic syndrome, progressive renal failure
and bicytopenia (moderate anemia and mild to moderate thrombocytopenia) had immunofixation
of urinary proteins suggestive of IgG/Kappa restriction; a renal biopsy was compatible
with fibrillary glomerulonephritis – membranoproliferative pattern with IgG deposits.
An additional investigative propaedeutic provided the diagnosis of monoclonal gammopathy
of renal significance. A membranoproliferative pattern is one of the possible renal
lesions described in this medical entity. However, it is important to note that histological
changes by themselves are not sufficient to establish the diagnosis, which requires
an investigation of the clinical context and exclusion of multiple myeloma as an etiological
mechanism.
In the context of monoclonal gammopathies, the presence of cytopenia should always
raise a suspicion of possible multiple myeloma/lymphoproliferation. However, in the
present case, this hypothesis was ruled out as described. Anemia and thrombocytopenia
were of mild to moderate intensity (mean hemoglobin: 8–9 g/dL; platelet count: 100–130 × 109/L).
They were investigated and attributed to a multifactorial process such as hematopoiesis
deficiency (vitamin B12 deficiency of disabsorptive etiology) with a chronic disease
component, acute inflammatory context due to urinary infection during hospitalization
and inadequate production of erythropoietin due to renal impairment. Peripheral blood
immunophenotyping was performed and showed no evidence of clonality in lymphocytes.
Monoclonal gammopathy of undetermined significance is considered a non-malignant or
pre-malignant lesion that does not induce lesions in target organs. Important intraclonal
heterogeneities have been observed but the detection of predictive factors of malignancy
remains a challenge as both cytogenetic factors (point mutations such as N-Ras, K-Ras,
MYC upregulation and gain/loss of chromosome 1q or 1p function) and aspects of bone
marrow microenvironment (angiogenesis, RANKL upregulation and interaction between
clonal cells and the stromal population) seem to be involved.
4
The follow-up of patients with monoclonal gammopathy of undetermined significance
has identified some cases in which there is renal damage as a consequence of renal
deposition of clonal components or due to alternative mechanisms resulting from the
action of clonal B cells and bone marrow that does not present enough plasma cell
infiltration to characterize multiple myeloma. Therefore, in 2012, the International
Kidney and Monoclonal Gammopathy Research Group defined a new entity named monoclonal
gammopathy of renal significance.
3
In monoclonal gammopathy of renal significance, the effector component corresponds
to a small B cell clone whose determination of clonality can be challenging. Thus,
renal biopsy with electron microscopy and immunohistochemistry is fundamental in the
investigation and diagnosis; this strategy allows the identification of the pattern
of renal deposits (which, by electron microscopy, can be organized/structured or not).
Different mechanisms have been described for renal failure in monoclonal gammopathies,
such as deposition and precipitation of M proteins in different renal compartments
such as glomeruli, vessels and the interstitium,
5
dysregulation of alternative pathways of complements and immunological mechanisms.
6
Similar renal lesions can also occur in lymphoproliferative diseases with the prevalence
of lesions changing according to the disease. Among small cell lymphomas/chronic lymphocytic
leukemia there is a predominance of membranoproliferative glomerulonephritis, followed
by minimal change disease and amyloid light-chain amyloidosis. In lymphoplasmacytic
lymphoma, non-Hodgkin's lymphoma and mantle cell lymphoma, there is predominance of
renal amyloid light-chain amyloidosis, followed by membranoproliferative glomerulonephritis.
7
The goal of treatment of patients with monoclonal gammopathy of renal significance
is to stop the natural evolution of the disease to prevent progress to end-stage renal
disease. It is important to emphasize that renal transplantation without previous
treatment might have a significant risk of graft loss, since the mechanism of injury
remains in full activity. Thus, the great benefits of early recognition of possible
cases with this diagnosis can be implied.
8
Conclusions
As a new entity whose diagnosis and treatment in early stages has a great impact on
prognosis, this case report aims to emphasize the heterogeneity of clinical and histological
presentations of monoclonal gammopathy of renal significance. It is crucial to consider
this possibility in cases of patients with monoclonal gammopathy and renal dysfunction
of ill-defined etiology. In this investigative process, a detailed histopathological
analysis is fundamental. In the present case, there was no benefit in starting specific
treatment as the patient was already on renal replacement therapy without prospect
of renal transplant.
Conflicts of interest
The authors declare no conflicts of interest.